Donor cell myelodysplastic syndrome after allogeneic stem cell transplantation responding to donor lymphocyte infusion: Case report and literature review

American Journal of Hematology

Volumn 76, Issue 4, 2004, Pages 389-394

  Komrokji, Rami ^a,b   Ifthikharuddin, Jainulabdeen J ^a   Felgar, Raymond E ^a   Abboud, Camille N ^a   Wedow, Lucy A ^a   Connaughton, Anna ^a   Bennett, John M ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b STRONG MEMORIAL HOSPITAL   (United States)

Author keywords

Allogeneic stem cell transplantation; Donor cell; Donor lymphocyte infusion; Myelodysplastic syndrome

Indexed keywords

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD DONOR; CASE REPORT; CHIMERA; CLINICAL FEATURE; DISEASE COURSE; HEMATOPOIESIS; HUMAN; LYMPHOCYTE TRANSFUSION; MALE; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; RELAPSE; REVIEW; SIBLING;

ANEMIA, REFRACTORY; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; BONE MARROW; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; EPSTEIN-BARR VIRUS INFECTIONS; GRAFT SURVIVAL; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY; HUMANS; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS; VIREMIA;

EID: 3342965841     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20111     Document Type: Review

References (22)

1. Bennelt JM, Komrokji R, Kouides PA. The myelodysplastic syndromes. In: Abeloff MD, Armilage JO, Niederhuber JE, et al. editors. Clinical oncology. 3rd ed. New York: Churchill Livingstone; 2004. Chapter 105. p 2849-2881.
2. Deeg HJ, Appelbaum FR. Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. Leuk Res 2000;24:653-663.
3. Fialkow PJ, Thomas ED, Bryant JI, Neiman PE. Leukaemic transformation of engrafted human marrow cells in vivo. Lancet 1971;1:251-255.
4. Cooley LD, Sears DA, Udden MM, Harrison WR, Baker KR. Donor cell leukemia: report of a case occurring 11 years after allogeneic bone marrow transplantation and review of the literature. Am J Hematol 2000;63:46-53.
5. Boyd CN, Ramberg RC, Thomas ED. The incidence of recurrence of leukemia in donor cells after allogeneic bone marrow transplantation. Leuk Res 1982;6:833-837.
6. Shekhter-Levin S, Bloom EJ, Swerdlow SH, Sherer ME, Wald N, Gollin SM. Acquired monosomy 7 in donor cells in a patient treated for acute lymphoblastic leukemia with bone marrow transplantation. Cancer Genet Cytogenet 1997;95:190-197.
7. Lowsky R, Fyles G, Minden M, et al. Detection of donor cell derived acute myelogenous leukaemia in a patient transplanted for chronic myelogenous leukaemia using fluorescence in situ hybridization. Br J Haematol 1996;93:163-165.
8. Abeliovich D, Yehuda O, Nagler A, et al. Predominant 45,X,Y karyotype in donor cells after allogeneic BMT: cytogenetic and molecular analysis. Cancer Genet Cytogenet 1996;86:1-7.
9. Okamoto T, Kanamura A, Okada M, et al. Myelodysplastic changes in three cases within 100 days after allogeneic bone marrow transplantation. Int J Hematol 1996;63:155-160.
10. Deeg HJ. Marrow stroma in MDS: culprit or bystander? Leuk Res 2002;26:687-688.
11. Flores-Figueroa E, Gutierrez-Espindola G, Guerrero-Rivera S, Pizzuto-Chavez J, Mayani H. Hematopoietic progenitor cells from patients with myelodysplastic syndromes: in vitro colony growth and long-term proliferation. Leuk Res 1999;23:385-394.
12. Coutinho LH, Geary CG, Chang J, Harrison C, Testa NG. Functional studies of bone marrow haemopoietic and stromal cells in the myelodysplastic syndrome (MDS). Br J Haematol 1990;75:16-25.
13. Aizawa S, Nakano M, Iwase O, Toyama K, Shima D, Handa H. Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro. Leuk Res 1999;23:239-246.
14. Flores-Figueroa E, Gutierrez-Espindola G, Montesinos JJ, Arana-Trejo RM, Mayani H. In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. Leuk Res 2002;26:677-686.
15. Deeg HJ, Socie G. Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood 1998;91:1833-1844.
16. Deeg HJ, Witherspoon RP. Risk factors for the development of secondary malignancies after marrow transplantation. Hematol Oncol Clin North Am 1993;7:417-429.
17. Thomas ED, Bryant JI, Buckner CD, et al. Leukemic transformation of engrafted human marrow. Transplant Proc 1972;4:567-570.
18. Krueger GRF, Kudlimay D, Ramon A, Klueppelberg U, Schumacher K. Demonstration of active and latent Epstein-Barr virus and human herpes virus-6 infections in bone marrow cells of patients with myelodysplastic and chronic myeloproliferative diseases. In Vivo 1994;8:533-542.
19. + progenitor cells by human cytomegalovirus: evidence for inhibition of hematopoiesis and viral replication. Blood 1996;88:1277-1283.
20. Miyahara M, Shimamoto Y, Yamada H, Shibata K, Matsuzaki M, Ono K. Cytomegalovirus-associated myelodysplasia and thrombocytopenia in an immunocompetent adult. Ann Hematol 1997;74:99-101.
21. Luznik L, Fuchs EJ. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control 2002;9:123-137.
22. Liu F, Poursine-Laurent J, Wu HY, Link DC. Interleukin-6 and the granulocyte colony-stimulating factor receptor are major independent regulators of granulopoiesis in vivo but are not required for lineage commitment or terminal differentiation. Blood 1997;90:2583-2590.